ストックスクリーナーアプリを入手
12.74
0.71%
0.03
前日終値:
$12.71
開ける：
$12.66
24時間の取引高:
26,634
Relative Volume:
0.01
時価総額：
$198.59M
収益：
$10.73M
当期純損益:
$-455.74M
株価収益率:
-3.5818
EPS:
-3.5569
ネットキャッシュフロー:
$-502.70M
1週間 パフォーマンス:
-6.36%
1か月 パフォーマンス:
-6.91%
6か月 パフォーマンス:
-73.86%
1年 パフォーマンス:
-49.96%
1日の値動き範囲:
$12.66
$12.86
1週間の範囲:
$12.63
$14.18
52週間の値動き範囲:
$11.95
$73.06
Atrium Therapeutics Inc Stock (RNA) Company Profile
Compare RNA vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RNA
Atrium Therapeutics Inc
|
12.80 | 197.20M | 10.73M | -455.74M | -502.70M | -3.5569 |
VRTX
Vertex Pharmaceuticals Inc
|
438.92 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
752.00 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
800.33 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.48 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.76 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Atrium Therapeutics Inc Stock (RNA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-11 | 開始されました | Wells Fargo | Overweight |
| 2025-09-17 | 開始されました | Roth Capital | Buy |
| 2025-07-10 | 再開されました | Goldman | Buy |
| 2025-06-24 | 開始されました | Bernstein | Outperform |
| 2025-06-17 | 開始されました | Wolfe Research | Outperform |
| 2025-06-11 | 開始されました | Raymond James | Strong Buy |
| 2025-03-13 | 開始されました | Citigroup | Buy |
| 2025-03-12 | 開始されました | BMO Capital Markets | Outperform |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-12-20 | 開始されました | H.C. Wainwright | Buy |
| 2024-11-26 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-09-24 | 開始されました | Goldman | Buy |
| 2024-08-28 | 開始されました | Barclays | Overweight |
| 2024-05-03 | 開始されました | BofA Securities | Buy |
| 2024-03-14 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-05-22 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-03-31 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-07-20 | 開始されました | Chardan Capital Markets | Buy |
| 2022-07-12 | 開始されました | Raymond James | Strong Buy |
| 2021-09-07 | 開始されました | Evercore ISI | Outperform |
| 2021-06-17 | 開始されました | Needham | Buy |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2020-07-07 | 開始されました | Cowen | Outperform |
| 2020-07-07 | 開始されました | Credit Suisse | Outperform |
| 2020-07-07 | 開始されました | SVB Leerink | Outperform |
| 2020-07-07 | 開始されました | Wells Fargo | Overweight |
すべてを表示
Atrium Therapeutics Inc (RNA) 最新ニュース
Atrium Therapeutics (RNA) price target decreased by 65.57% to 25.50 - MSN
Fierce Biotech Fundraising Tracker '26: Vivatides' $54M series A; Life Bio lures $80M - Fierce Biotech
Atrium Therapeutics Inc. Live Share Prices and Trades. RNA.US Live Streaming Share Prices. - London South East
T. Rowe Price holds 1.55M Atrium shares (10.0%) (NASDAQ: RNA) - Stock Titan
Stock List: Research Stocks from Around the World - GuruFocus
Atrium Therapeutics Inc. (RNA) Stock Price Quote Today & Current Price Chart - Capital.com
Atrium Therapeutics Inc. (RNA) Stock Price Quote Today & Current Price Chart | Capital.com Australia - capital.com
RNA PE Ratio & Valuation, Is RNA Overvalued - Intellectia AI
Mast Multialternative Strategy Fund's Atrium Therapeutics Inc(RNA) Holding History - GuruFocus
Atrium Therapeutics, Inc.(NasdaqGS:RNA) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
RNA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Stephanie Kenney Net Worth (2026) - GuruFocus
Novartis acquisition spin-off pioneers RNA therapeutics for the heart - Pharma Voice
Rocio Martin Hoyos Net Worth (2026) - GuruFocus
Brendan R. Winslow Net Worth (2026) - gurufocus.com
Atrium Mortgage Investment (TSE:AI) Given a C$13.12 Price Target at Fundamental Research - Defense World
Atrium Therapeutics, Inc.: Revenue and Earnings Analysts Forecasts Revisions | RNA | US04965N1046 - marketscreener.com
Finance Watch: Market Struggles On Iran War, Jobs Data, Impacting Biopharma Stocks - Citeline News & Insights
Atrium Therapeutics Inc. (NASDAQ: RNA)Share Price and Research - intelligentinvestor.com.au
Tenaya, Alnylam join in $1B+ cardio deal for novel genetic targets - BioWorld MedTech
Rx Rundown: EveryOne Medicines, Atrium Therapeutics, Moderna and more - Medical Marketing and Media
RNA SEC FilingsAtrium Therapeutics, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Atrium Therapeutics Inc Share Price USD0.001 - Hargreaves Lansdown
Atrium Therapeutics Inc. share price - Capital.com
Atrium Tx launches with Avidity's RNA ticker and cardio assets - bioworld.com
Atrium Therapeutics, Inc. (RNA): An Insightful Analysis of a Biotech Challenger with a $2.28 Billion Market Cap - DirectorsTalk Interviews
Atrium Therapeutics Launches with $270M to Advance RNA Therapies for Rare Genetic Cardiomyopathies - HLTH
Atrium Therapeutics, Inc.(NasdaqGS: RNA) added to NASDAQ Composite Index - marketscreener.com
Atrium Therapeutics Launches With $270M for RNA Therapies Addressing Rare Cardio Conditions - MedCity News
Novartis completes $12 billion acquisition of Avidity Biosciences - Indian Pharma Post
RNA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Atrium Therapeutics Stock Pre-Market (-4.5%): Launch as Public Company Post-Spin-Off - Trefis
Avidity Biosciences (NASDAQ:RNA) Reaches New 12-Month LowHere's What Happened - MarketBeat
Q4 Earnings Estimate for CVE:DWS Issued By Atrium Research - Defense World
Novartis completes $12 billion Avidity Biosciences acquisition By Investing.com - Investing.com Canada
Atrium Arises From Novartis’s Avidity Buyout - Citeline News & Insights
Avidity (RNA) Moves Date for Shareholder Vote on Novartis Merger - Finviz
Merger cashout for Avidity Biosciences (RNA) director Simona Skerjanec - Stock Titan
Avidity Biosciences (RNA) CMO options cashed out in $72 Novartis buyout - Stock Titan
Avidity Biosciences (RNA) CLO disposes stock, options in Novartis merger - Stock Titan
[Form 4] Avidity Biosciences, Inc. Insider Trading Activity - Stock Titan
Merger cash-out: Avidity Biosciences (RNA) officer’s options and shares disposed - Stock Titan
Novartis buyout: Avidity Biosciences (NASDAQ: RNA) director’s equity cashed out - Stock Titan
Avidity Biosciences (RNA) CTO equity disposed in $72 Novartis merger - Stock Titan
Avidity Biosciences shareholders approve merger with Novartis By Investing.com - Investing.com Australia
Novartis (NVS) Backs Atrium Therapeutics' Launch with $270M Funding - GuruFocus
Atrium spins out of Avidity, aiming to target rare heart diseases with RNA - BioPharma Dive
Operating expenses (excl. COGS) of Avidity Biosciences, Inc. – NASDAQ:RNAM - TradingView
Avidity-Novartis deal spins out Atrium Therapeutics - The Pharma Letter
Atrium arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates - Fierce Biotech
Avidity Biosciences (NASDAQ:RNA) Sets New 52-Week HighHere's What Happened - MarketBeat
Atrium Therapeutics Inc (RNA) 財務データ
収益
当期純利益
現金流量
EPS
Atrium Therapeutics Inc (RNA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Boyce Sarah | President and CEO |
Jan 21 '26 |
Sale |
72.45 |
14,387 |
1,042,338 |
269,007 |
| Flanagan W. Michael | Chief Scientific Officer |
Jan 21 '26 |
Sale |
72.45 |
6,534 |
473,388 |
85,093 |
| MacLean Michael F | Chief Financial Officer |
Jan 21 '26 |
Sale |
72.45 |
4,542 |
329,068 |
59,290 |
| LEVIN ARTHUR A | Director |
Jan 21 '26 |
Sale |
72.45 |
1,758 |
127,367 |
16,562 |
| McCarthy Teresa | Chief Human Resources Officer |
Jan 21 '26 |
Sale |
72.45 |
2,929 |
212,206 |
113,938 |
| Boyce Sarah | President and CEO |
Jan 07 '26 |
Sale |
72.23 |
8,576 |
619,444 |
283,394 |
| Calderaro Charles III | Chief Technical Officer |
Jan 07 '26 |
Sale |
72.23 |
3,727 |
269,201 |
49,797 |
| McCarthy Teresa | Chief Human Resources Officer |
Jan 07 '26 |
Sale |
72.23 |
1,965 |
141,932 |
116,867 |
| Moriarty John B | Chief Legal Officer |
Jan 07 '26 |
Sale |
72.23 |
2,374 |
171,474 |
74,557 |
| MacLean Michael F | Chief Financial Officer |
Jan 07 '26 |
Sale |
72.23 |
1,974 |
142,582 |
63,832 |
0.62%
大文字化:
|
ボリューム (24 時間):